OTC: PHMMF - Pharma Mar, S.A.

Yield per half year: +23.85%
Dividend yield: +2.09%
Sector: Healthcare

Share chart Pharma Mar, S.A.

Extended chart Simple chart
Financial Markets by TradingView

About Pharma Mar, S.A.

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, France, rest of EU, the United States, and internationally. The company operates through Oncology and RNA interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca for treating patients with small cell lung cancer.

more details
The company also develops PM14, which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trial for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trial for treating solid tumors; Tivanisiran, which is in Phase III clinical trial for the treatment of dry eye disease; and SYL1801 that is in phase II clinical trial for treating macular degeneration. In addition, it engages in the development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

ISIN ES0169501022
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 2.09
Дивиденд ао 0.6094
Сайт https://www.pharmamar.com
Цена ао 102.08
Change price per day: 0% (88.183)
Change price per week: 0% (88.183)
Change price per month: -13.61% (102.08)
Change price per 3 month: +8.77% (81.07)
Change price per half year: +23.85% (71.2)
Change price per year: +228.43% (26.85)
Change price per 3 year: +0.1511% (88.05)
Change price per 5 year: +5 343.4% (1.62)
Change price per year to date: +8.77% (81.07)
All parameters

Underestimation

Title Value Grade
P/S 7.83 1
P/BV 6.57 1
P/E 52.4 3
EV/EBITDA 1809.69 1
Total: 2.88

Efficiency

Title Value Grade
ROA, % 7.94 2
ROE, % 13.63 4
Total: 1.83

Dividends

Title Value Grade
Div yield, % 2.09 5.23
DSI 0.9286 9.29
Total: 4.8

Debt

Title Value Grade
Debt/EBITDA 120.7 0
Total: 7.2

Growth impulse

Title Value Grade
Yield Revenue, % -17.13 0
Yield Ebitda, % -146.43 0
Yield EPS, % -74.66 0
Total: 0
More

More

Institutions Volume Share, %
Legato Capital Management LLC 3481 0.02



Head Job title Payment Year of birth
Mr. Jose Maria Fernandez Sousa-Faro Ph.D. Founder, Executive Chairman, CEO & President 320.14k
Mr. Pedro Francisco Fernandez Puentes Executive Vice-Chairman 135.03k
Mr. Juan Carlos-Torres Carretero Founder N/A 1949 (76 years)
Ms. María Luisa de Francia Caballero Chief Financial Officer N/A
Mr. José Luis Moreno Martinez-Losa Head of Capital Markets & Investor Relations N/A
Mr. Juan Gomez Pulido General Counsel & Secretary of the Board of Directors N/A
Ms. Sandra Llamera Sanchez Global Compliance Head N/A
Ms. Lara Vadillo Communication Director N/A
Ms. Belén Sopesén Veramendi Ph.D. Director of Corporate Development N/A
Mr. Luis Rupérez Cuenca Director of Human Resources & IT N/A

Address: Spain, Madrid, Avenida de los Reyes. 1 - open in Google maps, open in Yandex maps
Website: https://www.pharmamar.com